Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 207

Similar articles for PubMed (Select 23978351)

1.

Phenotypic features of Crohn's disease associated with failure of medical treatment.

Moran GW, Dubeau MF, Kaplan GG, Yang H, Seow CH, Fedorak RN, Dieleman LA, Barkema HW, Ghosh S, Panaccione R; Alberta Inflammatory Bowel Disease Consortium.

Clin Gastroenterol Hepatol. 2014 Mar;12(3):434-42.e1. doi: 10.1016/j.cgh.2013.08.026. Epub 2013 Aug 24.

PMID:
23978351
2.

Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience.

Yoshino T, Matsuura M, Minami N, Yamada S, Honzawa Y, Kimura M, Koshikawa Y, Madian A, Toyonaga T, Nakase H.

Intest Res. 2015 Jul;13(3):266-73. doi: 10.5217/ir.2015.13.3.266. Epub 2015 Jun 9.

3.

Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.

George LA, Gadani A, Cross RK, Jambaulikar G, Ghazi LJ.

Dig Dis Sci. 2015 Jun 27. [Epub ahead of print]

PMID:
26115749
4.

Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn's Disease: A Comparison of Effectiveness and Safety.

Liu J, Sylwestrzak G, Ruggieri AP, DeVries A.

J Manag Care Spec Pharm. 2015 Jul;21(7):559-66.

PMID:
26108380
5.

Long-term course of Crohn's disease in Japan: Incidence of complications, cumulative rate of initial surgery, and risk factors at diagnosis for initial surgery.

Sato Y, Matsui T, Yano Y, Tsurumi K, Okado Y, Matsushima Y, Koga A, Takahashi H, Ninomiya K, Ono Y, Takatsu N, Beppu T, Nagahama T, Hisabe T, Takaki Y, Hirai F, Yao K, Higashi D, Futami K, Washio M.

J Gastroenterol Hepatol. 2015 Jun 11. doi: 10.1111/jgh.13013. [Epub ahead of print]

PMID:
26094852
6.

Vagotomy and subsequent risk of Parkinson's disease.

Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sørensen HT.

Ann Neurol. 2015 May 29. doi: 10.1002/ana.24448. [Epub ahead of print]

PMID:
26031848
7.

Prevalence of Antibodies Against JC Virus in Serum of Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.

Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A.

Clin Gastroenterol Hepatol. 2015 May 19. pii: S1542-3565(15)00698-9. doi: 10.1016/j.cgh.2015.05.022. [Epub ahead of print]

PMID:
26001336
8.

Prevalence and risk factors of acute lower gastrointestinal bleeding in crohn disease.

Li G, Ren J, Wang G, Wu Q, Gu G, Ren H, Liu S, Hong Z, Li R, Li Y, Guo K, Wu X, Li J.

Medicine (Baltimore). 2015 May;94(19):1-7. doi: 10.1097/MD.0000000000000804.

PMID:
25984665
9.

Patterns and Predictors of Long-term Nonuse of Medical Therapy Among Persons with Inflammatory Bowel Disease.

Melesse DY, Targownik LE, Singh H, Blanchard JF, Bernstein CN.

Inflamm Bowel Dis. 2015 Jul;21(7):1615-22. doi: 10.1097/MIB.0000000000000418.

PMID:
25970546
10.
11.

Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease.

Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S.

J Crohns Colitis. 2015 May 9. pii: jjv080. [Epub ahead of print]

PMID:
25958059
12.

Ashkenazi jewish origin protects against formation of antibodies to infliximab and therapy failure.

Ungar B, Haj-Natour O, Kopylov U, Yavzori M, Fudim E, Picard O, Loebstein R, Lahat A, Maor Y, Avidan B, Lang A, Weiss B, Chowers Y, Eliakim R, Ben-Horin S.

Medicine (Baltimore). 2015 May;94(18):e673. doi: 10.1097/MD.0000000000000673.

PMID:
25950682
13.

Thyroid cancer and T lymphoblastic leukemia in crohn disease: a case report and literature review.

Byun JM, Baek SK, Yoon HJ, Kim SY, Maeng CH, Park TS, Kim HJ, Choi YY, Um YJ.

Lab Med. 2015 Spring;46(2):140-5. doi: 10.1309/LMU4KMJDRM3AD6FQ.

PMID:
25918193
14.

Toxicity and response to thiopurines in patients with inflammatory bowel disease.

Goldberg R, Irving PM.

Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):891-900. doi: 10.1586/17474124.2015.1039987. Epub 2015 Apr 27.

PMID:
25915575
15.

Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.

Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, Rick J, Mack D, Bousvaros A, Rosh J, Grossman A, Saeed S, Kay M, Boyle B, Oliva-Hemker M, Keljo D, Pfefferkorn M, Faubion W, Kappelman MD, Sudel B, Markowitz J, Hyams JS.

Clin Gastroenterol Hepatol. 2015 Apr 21. pii: S1542-3565(15)00412-7. doi: 10.1016/j.cgh.2015.04.010. [Epub ahead of print]

PMID:
25911120
16.

Incidence and Risk Factors for Urolithiasis in Patients with Crohn's Disease.

Kim MJ, Woo SY, Kim ER, Hong SN, Chang DK, Rhee PL, Kim JJ, Rhee JC, Kim YH.

Urol Int. 2015 Apr 17. [Epub ahead of print]

PMID:
25895526
17.

Rac1 Polymorphisms and Thiopurine Efficacy in Children with Inflammatory Bowel Disease.

Lev-Tzion R, Renbaum P, Beeri R, Ledder O, Mevorach R, Karban A, Koifman E, Efrati E, Muise AM, Chowers Y, Turner D.

J Pediatr Gastroenterol Nutr. 2015 Apr 10. [Epub ahead of print]

PMID:
25885881
18.

Ionizing radiation exposure is still increasing in Crohn's disease: Who should be blamed?

Magro F, Coelho R, Guimarães LS, Silva M, Peixoto A, Lopes S, Macedo G.

Scand J Gastroenterol. 2015 Apr 16:1-12. [Epub ahead of print]

PMID:
25881793
19.

Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.

Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP.

Aliment Pharmacol Ther. 2015 Jun;41(11):1141-8. doi: 10.1111/apt.13195. Epub 2015 Apr 13.

PMID:
25864945
20.

Routinely established skewed thiopurine metabolism leads to a strikingly high rate of early therapeutic failure in patients with inflammatory bowel disease.

Kreijne JE, Seinen ML, Wilhelm AJ, Bouma G, Mulder CJ, van Bodegraven AA, de Boer NK.

Ther Drug Monit. 2015 Apr 4. [Epub ahead of print]

PMID:
25853923
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk